Adverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: A retrospective cohort study
Open Access
- 11 August 2025
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (12) , 3461-3470
Abstract
Aims: Adverse drug reactions (ADRs) are a key driver of missed doses of anti‐tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR‐driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses. Methods: In this retrospective cohort study, adults (≥18 years) who began the standard 6‐month drug‐sensitive anti‐TB regimen in an outpatient facility in Riga, Latvia (May 2015–September 2022) and missed at least one dose of treatment were included. Data were collected from medical records and observed therapy records. Missed doses were subdivided into early discontinuation or sporadically missed. Descriptive analyses and lasagne plots were used. Results: Across 174 patients, 54 (31.0%, CI: 24.2–37.9%) missed doses due to ADRs. Of 31 320 doses, 4217 (13.5%, CI: 13.1–13.9%) were missed, 20.9% (880/4217, CI: 19.6–22.1%) were due to ADRs. Eighteen (10.3%) of the 174 patients discontinued treatment early, two of which (11.1%) were due to ADRs. Doses missed due to ADRs caused longer yet less frequent periods of sporadic missed doses: 56.4% (479/849) of sporadic missed doses were 1 day in length vs . only 9.1% (7/77) for ADR‐related ones. Hepatobiliary disorders were the leading ADR group causing missed doses. Hepatobiliary ADRs caused long median durations of missed doses (median 15.0, CI: 13.0–22.0). Conclusion: Our study underscores the importance of ADRs as a cause of missed doses of treatment, particularly hepatobiliary disorders. Regimens that are less prone to ADRs and strong healthcare system support structures for patients with ADRs are required to minimize missed doses, reducing unfavourable outcomes.Keywords
All Related Versions
Funding Information
- Medical Research Council (MR/N013166/1)
This publication has 27 references indexed in Scilit:
- Concomitant Treatment of Tuberculosis and Hepatitis C Virus in Coinfected Patients Using Serum Drug Concentration MonitoringOpen Forum Infectious Diseases, 2023
- Global prevalence of hepatitis B or hepatitis C infection among patients with tuberculosis disease: systematic review and meta-analysiseClinicalMedicine, 2023
- High Rates of Drug-induced Liver Injury in People Living With HIV Coinfected With Tuberculosis (TB) Irrespective of Antiretroviral Therapy Timing During Antituberculosis Treatment: Results From the Starting Antiretroviral Therapy at Three Points in TB TrialClinical Infectious Diseases, 2019
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Burden of liver diseases in the worldJournal of Hepatology, 2019
- Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosisCochrane Database of Systematic Reviews, 2016
- Lasagna PlotsEpidemiology, 2010
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Monitoring for Hepatotoxicity: What Is the Predictive Value of Liver “Function” Tests?Clinical Pharmacology & Therapeutics, 2009
- Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year PeriodGastroenterology, 2005